摘要
目的:探讨黄芪糖蛋白对佐剂性关节炎大鼠脾组织细胞凋亡的影响,为黄芪糖蛋白作为一种新的中药来源的免疫抑制剂获得进一步的证据。方法:建立大鼠佐剂性关节炎模型,治疗2周,再观察1周,造模后22d,取脾组织,使用原位标记(TUNEL)检测脾组织的原位细胞凋亡情况,使用免疫组织化学方法检测脾组织凋亡相关因子Fas、FasL、Bax、Bcl-2及转录因子Foxp3的蛋白表达情况。结果:黄芪糖蛋白低、中、高剂量组均可增加脾细胞的凋亡率(P<0.05或P<0.01),同时高剂量组降低大鼠脾组织中Fas、FasL、Bax的蛋白表达水平(P<0.01),升高Bcl-2的蛋白表达水平(P<0.01)。黄芪糖蛋白低剂量组对四种蛋白的表达有回调作用(P<0.01)。黄芪糖蛋白低、中剂量组可升高大鼠脾组织Foxp3的蛋白表达水平(P<0.01)。结论:黄芪糖蛋白可诱导佐剂性关节炎大鼠脾组织细胞凋亡,且调节Fas、FasL、Bax、Bcl-2及转录因子Foxp3的蛋白表达水平。
Objective： To investigate the immunosuppressive activity of Astragalus glycoprotein （AGP） in vitro and in vivo from multiple levels and angles and to provide experimental evidence for researching and applying of AGP by studying on the effect of AGP on apoptosis of spleen cells in adjuvant arthritis （AA） rats. Methods： We established AA rat model with 2 weeks of treatment and another week for observation. 22 days after establishing the AA rat model, apoptosis of spleen cells in situ from the model were tested by TUNEL, and immunohistochemical method was adopted to test the expression of its related factors including Fas, FasL, Bax, Bcl-2 and transcription factor Foxp3. Results： It was found that each dose of AGP, including low-dose, medium-dose and high-dose AGP, could increase the apoptosis rate of spleen cells （P〈0.05 or P〈0.01）. Meanwhile, high-dose AGP lowered the protein expression levels of Fas, FasL, Bax in spleen （P〈0.01）, while improved the protein expression level of Bcl-2 （P〈0.01）. Low-dose AGP had a regulatory effect on the expression of these four kinds of protein （P〈0.01）. Low-dose and medium-dose AGP also could raise the protein expression level of Foxp3 （P〈0.01）. Conclusion： These findings indicate that AGP can induce the apoptosis of spleen cells in AA rats, and regulate the protein expression levels of Fas, FasL, Bax, Bcl-2 and the transcription factor Foxp3.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2014年第5期1711-1715,共5页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
National Key Technology R&D Program(No.2011BAI07B01)
International S&T Cooperation Program of China(No.2013DFA30700)
Scientii c Research Innovation Team Program of Beijing University of Chinese Medicine(No.2011-CXTD-05)
Shanxi Province Key Technologies R&D Program of China(No.20130321031-01)
Scientific Research Project of Shanxi Province Health Department(No.201201099)
Indenpent Project of Shanxi University of Traditional Chinese Medicine(No.2011LC05)~~
